Life Sciences Blog
As Seen In
In an interview with The Lawyer, WSG member Simon McArdle, Partner at Shoosmiths, shares his advice to GCs for initial approach to implementation of legal tech solutions. McArdle gives his advice on how to ensure the best strategic implementation...
Services
Region
Industries
- Agriculture
- Corporate & Business
- Crossborder Trade & Investment
- Dispute Resolution
- Employment & Labor
- Energy & Natural Resources
- Environmental
- Financial Services
- Government & Public Sector
- Healthcare & Pharmaceuticals
- Hospitality, Media & Leisure
- Industrial & Manufacturing
- Insurance
- Life Sciences
- Real Estate & Construction
- Retail & Distribution
- Taxation
- Technology
- Telecommunications
- Transportation
Recent Posts
- Blog: Waller Law BlogRepresentation and Warranty Insurance (RWI) in healthcare provider deals: what you need to know for year-end 2021Posted on October 20, 2021 by Dealmakers with a mandate to close by year-end should plan ahead and fast-track due diligence processes.
- Blog: Ireland IP & Technology Law BlogOld EU SCCs now repealedPosted on September 29, 2021 by Davinia BrennanWhen the European Commission adopted the new EU Standard Contractual Clauses (new SCCs) for international data transfers earlier this year, we highlighted 3 key dates to be aware of. As one of those dates – 27 September 2021 – has now passed, its timely to remind ourselves why those dates are important. 27 June 2021...Continue Reading…
- Blog: Homeostasis: Dykema Health Care Law BlogImportant Enforcement Updates on No Surprises Act and Transparency RequirementsPosted on September 13, 2021 by Kathleen A. Reed, David R. PadalinoHealth plans and insurers will have a little more time to comply with some of the multitude of new requirements under the Consolidated Appropriations Act (“CAA”). On August 20, 2021, the Departments of Labor, Health and Human Services, and the Treasury (the “Departments”) issued an FAQ updating plans and issuers on critical enforcement guidance for several CAA transparency measures. The Departments have acknowledged that plans and issuers are struggling to comply with the litany, and complexity, of transparency requirements the CAA imposes, going so far as to note that...
- Blog: Biologics BlogFederal Circuit Upholds Jury Award, Weighs in on Willfulness Standard, in Adynovate® DisputePosted on March 29, 2021 by According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s sale of its biologic product Adynovate® (Antihemophilic Factor (Recombinant), PEGylated). In Bayer Healthcare LLC v. Baxalta Inc., et al., Nos. 2019-2418, 2020-1017 (Fed. Cir. 2021), the circuit court upheld an award to Bayer [...]
